4/17
01:31 pm
arvn
Arvinas, Inc. (NASDAQ: ARVN) had its price target lowered by analysts at The Goldman Sachs Group, Inc. from $15.00 to $12.00. They now have a "neutral" rating on the stock.
Low
Report
Arvinas, Inc. (NASDAQ: ARVN) had its price target lowered by analysts at The Goldman Sachs Group, Inc. from $15.00 to $12.00. They now have a "neutral" rating on the stock.
4/10
05:48 pm
arvn
Arvinas, Inc. (ARVN): Among Stocks Under $10 that Will Triple [Yahoo! Finance]
Medium
Report
Arvinas, Inc. (ARVN): Among Stocks Under $10 that Will Triple [Yahoo! Finance]
4/9
09:23 am
arvn
Arvinas, Inc. (NASDAQ: ARVN) had its price target lowered by analysts at Truist Financial Co. from $65.00 to $21.00. They now have a "buy" rating on the stock.
Medium
Report
Arvinas, Inc. (NASDAQ: ARVN) had its price target lowered by analysts at Truist Financial Co. from $65.00 to $21.00. They now have a "buy" rating on the stock.
4/7
08:55 am
arvn
Arvinas, Inc. (NASDAQ: ARVN) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $81.00 price target on the stock.
Low
Report
Arvinas, Inc. (NASDAQ: ARVN) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $81.00 price target on the stock.
4/4
07:11 am
arvn
Arvinas Presents First-in-Human Data for Investigational Oral PROTAC ARV-102 Demonstrating Blood-Brain Barrier Penetration, and Central and Peripheral LRRK2 Degradation [Yahoo! Finance]
Low
Report
Arvinas Presents First-in-Human Data for Investigational Oral PROTAC ARV-102 Demonstrating Blood-Brain Barrier Penetration, and Central and Peripheral LRRK2 Degradation [Yahoo! Finance]
4/4
07:00 am
arvn
Arvinas Presents First-in-Human Data for Investigational Oral PROTAC ARV-102 Demonstrating Blood-Brain Barrier Penetration, and Central and Peripheral LRRK2 Degradation
Low
Report
Arvinas Presents First-in-Human Data for Investigational Oral PROTAC ARV-102 Demonstrating Blood-Brain Barrier Penetration, and Central and Peripheral LRRK2 Degradation
3/27
07:00 am
arvn
Arvinas Announces Oral Presentation at 2025 International Conference on Alzheimer’s & Parkinson’s Diseases
Low
Report
Arvinas Announces Oral Presentation at 2025 International Conference on Alzheimer’s & Parkinson’s Diseases
3/13
12:35 pm
arvn
Arvinas, Inc. (NASDAQ: ARVN) had its price target lowered by analysts at Morgan Stanley from $48.00 to $12.00. They now have an "equal weight" rating on the stock.
Low
Report
Arvinas, Inc. (NASDAQ: ARVN) had its price target lowered by analysts at Morgan Stanley from $48.00 to $12.00. They now have an "equal weight" rating on the stock.
3/13
11:43 am
arvn
Arvinas, Inc. (NASDAQ: ARVN) had its price target lowered by analysts at Guggenheim from $57.00 to $32.00. They now have a "buy" rating on the stock.
Low
Report
Arvinas, Inc. (NASDAQ: ARVN) had its price target lowered by analysts at Guggenheim from $57.00 to $32.00. They now have a "buy" rating on the stock.
3/13
07:49 am
arvn
Arvinas, Inc. (NASDAQ: ARVN) was downgraded by analysts at The Goldman Sachs Group, Inc. from a "buy" rating to a "neutral" rating. They now have a $15.00 price target on the stock, down previously from $70.00.
Medium
Report
Arvinas, Inc. (NASDAQ: ARVN) was downgraded by analysts at The Goldman Sachs Group, Inc. from a "buy" rating to a "neutral" rating. They now have a $15.00 price target on the stock, down previously from $70.00.
3/12
10:03 am
arvn
Arvinas, Inc. (NASDAQ: ARVN) was given a new $26.00 price target on by analysts at Wells Fargo & Company. They now have an "overweight" rating on the stock.
Medium
Report
Arvinas, Inc. (NASDAQ: ARVN) was given a new $26.00 price target on by analysts at Wells Fargo & Company. They now have an "overweight" rating on the stock.
3/12
10:03 am
arvn
Arvinas, Inc. (NASDAQ: ARVN) was given a new $20.00 price target on by analysts at BMO Capital Markets.
Medium
Report
Arvinas, Inc. (NASDAQ: ARVN) was given a new $20.00 price target on by analysts at BMO Capital Markets.
3/12
08:57 am
arvn
Arvinas, Inc. (NASDAQ: ARVN) had its price target lowered by analysts at Bank of America Co. from $54.00 to $28.00. They now have a "buy" rating on the stock.
Medium
Report
Arvinas, Inc. (NASDAQ: ARVN) had its price target lowered by analysts at Bank of America Co. from $54.00 to $28.00. They now have a "buy" rating on the stock.
3/12
07:22 am
arvn
Arvinas, Inc. (NASDAQ: ARVN) was downgraded by analysts at Wedbush from an "outperform" rating to a "neutral" rating. They now have a $12.00 price target on the stock, down previously from $57.00.
Medium
Report
Arvinas, Inc. (NASDAQ: ARVN) was downgraded by analysts at Wedbush from an "outperform" rating to a "neutral" rating. They now have a $12.00 price target on the stock, down previously from $57.00.
3/11
08:07 pm
arvn
Arvinas gets positive breast cancer data, but finds differentiation a hard sell [Yahoo! Finance]
Medium
Report
Arvinas gets positive breast cancer data, but finds differentiation a hard sell [Yahoo! Finance]
3/11
11:46 am
arvn
Arvinas Plummets 53% On Mixed Results For Its Pfizer-Tied Breast Cancer Drug [Yahoo! Finance]
Low
Report
Arvinas Plummets 53% On Mixed Results For Its Pfizer-Tied Breast Cancer Drug [Yahoo! Finance]
3/11
11:19 am
arvn
Arvinas, Inc. (NASDAQ: ARVN) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $81.00 price target on the stock.
Low
Report
Arvinas, Inc. (NASDAQ: ARVN) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $81.00 price target on the stock.
3/11
11:06 am
arvn
Arvinas, Inc. (NASDAQ: ARVN) was downgraded by analysts at Oppenheimer Holdings Inc. from an "outperform" rating to a "market perform" rating.
Low
Report
Arvinas, Inc. (NASDAQ: ARVN) was downgraded by analysts at Oppenheimer Holdings Inc. from an "outperform" rating to a "market perform" rating.
3/11
06:45 am
arvn
Arvinas and Pfizer Announce Positive Topline Results from Phase 3 VERITAC-2 Clinical Trial
High
Report
Arvinas and Pfizer Announce Positive Topline Results from Phase 3 VERITAC-2 Clinical Trial
3/7
05:11 pm
arvn
Arvinas, Inc. (NASDAQ: ARVN) had its price target lowered by analysts at Citigroup Inc. from $28.00 to $19.00. They now have a "neutral" rating on the stock.
Low
Report
Arvinas, Inc. (NASDAQ: ARVN) had its price target lowered by analysts at Citigroup Inc. from $28.00 to $19.00. They now have a "neutral" rating on the stock.
3/4
06:13 pm
arvn
Arvinas to Participate in Upcoming Investor Conferences [Yahoo! Finance]
Medium
Report
Arvinas to Participate in Upcoming Investor Conferences [Yahoo! Finance]
3/4
04:05 pm
arvn
Arvinas to Participate in Upcoming Investor Conferences
Medium
Report
Arvinas to Participate in Upcoming Investor Conferences
2/12
11:58 am
arvn
Arvinas, Inc. (NASDAQ: ARVN) had its price target raised by analysts at Oppenheimer Holdings Inc. from $40.00 to $45.00. They now have an "outperform" rating on the stock.
Low
Report
Arvinas, Inc. (NASDAQ: ARVN) had its price target raised by analysts at Oppenheimer Holdings Inc. from $40.00 to $45.00. They now have an "outperform" rating on the stock.
2/12
10:57 am
arvn
Arvinas, Inc. (NASDAQ: ARVN) had its "outperform" rating re-affirmed by analysts at BMO Capital Markets. They now have a $82.00 price target on the stock, down previously from $88.00.
Medium
Report
Arvinas, Inc. (NASDAQ: ARVN) had its "outperform" rating re-affirmed by analysts at BMO Capital Markets. They now have a $82.00 price target on the stock, down previously from $88.00.
2/12
10:35 am
arvn
Arvinas, Inc. (NASDAQ: ARVN) had its "buy" rating re-affirmed by analysts at Guggenheim. They now have a $57.00 price target on the stock.
Medium
Report
Arvinas, Inc. (NASDAQ: ARVN) had its "buy" rating re-affirmed by analysts at Guggenheim. They now have a $57.00 price target on the stock.